01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsRights Issue 2024NextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNextCell in the mediaEventsCompany PresentationsQ&A with CEO
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted

March 28, 2023

NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.

NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.

NextCell Pharma AB is a cell therapy company working in the development and commercialization of the mesenchymal stromal cell therapy product, ProTrans. This product, with its proprietary platform technology, is in clinical development for the treatment of autoimmune conditions, such as type I diabetes and inflammatory conditions such as viral pneumonia.

 

NextCell´s seminal study in type 1 diabetes, with their advanced therapeutic medicinal product, ProTrans, has been accepted for publication in the journal Diabetologia. The article, entitled, “Umbilical Cord-Derived Mesenchymal Stromal Cells Preserve Endogenous Insulin Production in Type 1 Diabetes: a Phase I/II Double-blinded, Placebo-controlled, Randomized trial” details how a single infusion of ProTrans can maintain the endogenous production of insulin, slowing the progression of the disease.

 

“It is fantastic to have our first study in type I diabetes published. This study has been the foundation for our clinical development programme in type I diabetes. The study, although small, presents strong data indicative of the effectiveness of ProTrans treatment in slowing diabetic disease development. Based on these data we have moved forward with a pediatric study investigating the efficacy of our drug product in newly diagnosed type I diabetics in the 7-21 age range, ”says Dr Mathias Svahn, CEO for NextCell Pharma.

 

The data reported in the manuscript was generated in collaboration with Professor Per-Ola Carlsson, Principal Investigator at Uppsala University and Karolinska Trial Alliance, Karolinska University Hospital, Huddinge, Sweden(Clinicaltrials.gov identifier NCT03406585).

 

For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel:08-735 5595
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com
 LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
 
 
 
About NextCell Pharma AB
NextCell is a celltherapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5%of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

 

‍

For more information about NextCell Pharma AB, please contact

Mathias Svahn, CEO
Patrik Fagerholm, CFO

Tel:08-735 5595
E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

 LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

‍

About NextCell Pharma AB

NextCell is a celltherapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5%of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

Download attachmentRead full press release on Cision (external link)
2023-12-13
NextCell Pharma has compiled a Q&A section
NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section. The questions and answers can be accessed via the link below.
Read moreRead more
2023-11-06
Repeated treatment with ProTrans is immunologically safe
NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.
Read moreRead more
2023-10-26
NextCell publishes its Year-End Report 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2023-10-10
NextCell signs an agreement for a new tissue product
NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.
Read moreRead more
2023-09-05
NextCell Pharma presents at the Advanced Therapies Europe conference
NextCell Pharma participates in Advanced Therapies Europe, a European conference in Portugal on advanced cell therapies. NextCell's CSO Dr. Lindsay Davies will talk about NextCell's platform technology and the internationally recognized research generated during the development of drug product ProTrans for type 1 diabetes.
Read moreRead more
2023-08-08
ProTrans and NextCell gain international attention
Results from Professor Per-Ola Carlsson, Principal Investigator for NextCell’s Phase-I/II study with ProTrans stromal cells for Type 1 Diabetes are now published and featured in the Up-front section of the current issue of Diabetologia. The article was selected by the Editor as worthy of special attention, for its high quality and interest to the diabetes field. Furthermore, the article has already been cited in an International scientific journal.
Read moreRead more
2023-07-27
NextCell publishes its Interim Report 3 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2023 – May 31, 2023 The report is available on the company’s website:  https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2023-07-05
Treatment start of severe pneumonia with high dose of ProTrans
NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans 19+SE (also called Protrans V) can start recruiting patients in the high dose group, which is the last dose group. Three patients treated with medium dose of ProTrans have been clinically evaluated and the data has been reviewed by the Data Safety Monitoring Board, which now allows continued treatment with high-dose ProTrans for severe pneumonia caused by COVID-19, Influenza, Human Metapneumovirus and RSV.
Read moreRead more
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept